Related Experiment Video

Updated: Jun 13, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance

Adrienne G Waks1,2,3, Olga Martínez-Sáez4,5,6, Paolo Tarantino1,2,7

  • 1Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Nature Reviews. Clinical Oncology
|September 13, 2024
PubMed

Insights

Novel HER2-targeted therapies are advancing for HER2-positive breast cancer. Understanding tumor biology and biomarkers is crucial for optimizing personalized treatment strategies and improving patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • HER2-positive breast cancer treatments are evolving with targeted therapies.
  • Current options include monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates, often combined with chemotherapy or endocrine therapy.

Purpose of the Study:

  • To review mechanisms of action for HER2-targeted agents.
  • To examine evidence for dual HER2 blockade in HER2-amplified tumors.
  • To explore biomarker roles in guiding future HER2+ breast cancer treatment strategies.

Main Methods:

  • Literature review of HER2-targeted therapies.
  • Analysis of clinical evidence for dual HER2 blockade.
  • Discussion of biomarker utility in personalized medicine.

Main Results:

  • HER2-targeted therapies offer personalized treatment options for HER2+ breast cancer.
  • Dual HER2 blockade shows promise in HER2-amplified tumors.
  • Biomarkers are key to optimizing treatment selection and patient outcomes.

Conclusions:

  • Deeper understanding of HER2+ breast cancer biology is needed to optimize novel agent responsiveness.
  • Biomarker-guided strategies are essential for future personalized treatment of HER2+ breast cancer.
  • The review discusses implications for future therapeutic approaches.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:29

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

86
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.8K